Shares of bioAffinity Technologies Inc (BIAF) are having a very good Tuesday, jumping more than 40%. The reason? A story about a 71-year-old former smoker that perfectly illustrates what the company's flagship product is supposed to do.

The company released a clinical case study detailing this patient's journey. He had multiple small lung nodules, which in the world of oncology is a classic diagnostic headache. The standard playbook often leads to an invasive biopsy—not a fun procedure. But instead of going straight to surgery, his doctor used bioAffinity's CyPath Lung test. The result came back: "Unlikely Malignancy."

So, they waited. A follow-up scan in October confirmed the nodules were benign. No biopsy needed. Crisis—and a risky, expensive procedure—averted.

"Multiple small nodules in a high-risk patient pose a diagnostic challenge," said Daya Nadarajah, MD, the patient's pulmonologist. He noted the negative test result provided the comfort needed to opt for watchful waiting instead of immediate intervention.

This is the dream scenario for a diagnostic test. bioAffinity's Chief Medical Officer, Gordon Downie, MD, PhD, spelled out the benefits: reducing patient anxiety and lowering healthcare costs by helping to avoid "expensive, invasive and often risky procedures when they are not necessary."

For investors, this case study is a tangible, human-proof-point for the product's value proposition. And it comes at a time when the financial story for CyPath Lung is getting very interesting. In 2025, revenue from the test soared 87% year-over-year. Even more impressively, the number of tests performed nearly doubled, up 99%. Management is now strategically pivoting, moving away from lower-margin lab services to double down on this high-growth flagship.

The stock reaction has been... enthusiastic, to say the least. Tuesday's surge follows a period of wild swings. The stock cooled off on Monday, but that was after a massive 120% rally last Friday, driven by those strong growth metrics. It's the kind of volatility you often see when a small biotech starts showing real commercial traction.

So, what's next? Everyone's eyes are now on the fourth-quarter earnings report, scheduled for March 30. Analysts are expecting a loss per share of $2.70 on revenue of $1.41 million. The company ended 2025 with $6.5 million in cash, bolstered by approximately $16.9 million in financings.

In short: a test worked as advertised for a real patient, the financials behind that test are accelerating sharply, and the market is taking notice. As of publication, bioAffinity Technologies shares were up 41.37% at $2.70.